Drug Trial Radar · NCT00921024
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Last checked: Nov 20, 2026Latest source record: Oct 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Jun 30, 2009
Primary completion
Feb 25, 2010
Study completion Mar 11, 2010
Sponsor
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of intravenous CXA 101 and comparator in complicated urinary tract infection
Conditions
- Complicated Urinary Tract Infection
Interventions
CXA-101Drug
intravenous
CeftazidimeDrug
intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) PopulationTime frame: TOC; 6-9 days after last study drug administration
- Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.Time frame: TOC; 6-9 days after last study drug administration
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Healthcare Partners Medical Group
Los Angeles, California
Compass Research, LLC
Orlando, Florida
Atlanta Institute for Medical Research, Inc.
Decatur, Georgia
Infectious Disease of Indiana, PSC
Indianapolis, Indiana
Mississippi Medical Research, LLC
Picayune, Mississippi
Great Falls Clinic, LLP
Butte, Montana
Remington-Davis, Inc. Clinical Research
Columbus, Ohio
Kreiskrankenhaus Backnang
Backnang, Germany
URO Forschungs GmbH
Berlin, Germany
Uniklinikum Giessen
Giessen, Germany
Evangelisches Krankenhaus Giessen Urologie
Giessen, Germany
Universitätsklinikum Schleswig Holstein Campus Lübeck
Lübeck, Germany
Brüderkrankenhaus St. Josef Paderborn
Paderborn, Germany
Urologische Klinik Dr. Castringius München-Planegg
Planegg, Germany
Samodzielny Publiczny Szpital Kliniczny nr 4 Katedra i Klinika Nefrologii
Lublin, Poland
Wojewódźki Szpital Specjalistyczny nr 1 Oddział Chorób Wewnętrznych
Tychy, Poland
Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych
Warsaw, Poland
Szpital Kliniczny Dzieciątka Jezus-Centrum Leczenia Obrażeń Klinika Urologii Ogólnej, Onkologicznej Czynnościowej
Warsaw, Poland
Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych
Warsaw, Poland
Wojewódźki Szpital Specjalistyczny Oddział Nefrologiczny
Wroclaw, Poland
Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ
Zamość, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.